Protocol for the Economic Evaluation of COVID-19 Pandemic Response Policies

Overview

Journal BMJ Open

Specialty General Medicine

Date 2021 Sep 15

PMID 34521677

Citations 3

Authors

Brandon Wen Bing Chua

Vinh Anh Huynh

Jing Lou

Fang Ting Goh

Hannah Clapham

Yot Teerawattananon

Hwee Lin Wee

Affiliations

Soon will be listed here.

Abstract

Introduction: Several treatment options are available for COVID-19 to date. However, the use of a combination of non-pharmaceutical interventions (NPIs) is necessary for jurisdictions to contain its spread. Although the implementation cost of NPIs may be low from the healthcare system perspective, it can be costly when considering the indirect costs from the societal perspective. COVID-19 vaccination campaigns have begun in several countries worldwide. Nonetheless, the quantity of vaccines available remain limited over the next 1 to 2 years. A tool for informing vaccine prioritisation that considers both cost and effectiveness will be highly useful. This study aims to identify the most cost-effective combination of COVID-19 response policies, using Singapore as an example.

Methods And Analysis: An age-stratified Susceptible-Exposed-Infectious-Recovered model will be used to generate the number of infections stratified by disease severity under different intervention scenarios. Polices of interest include test-trace-isolate, travel restriction, compulsory face mask and hygiene practices, social distancing, dexamethasone/remdesivir therapy and vaccination. The latest phase 3 trial results and the WHO Target Product Profiles for COVID-19 vaccines will be used to model vaccine characteristics. A cost (expected resource utilisation and productivity losses) and quality-adjusted life years (QALYs) will be attached to these outputs for a cost-utility analysis. The primary outcome measure will be the incremental cost-effectiveness ratio generated from the incremental cost of policy alternatives expressed as a ratio of the incremental benefits (QALYs gained). Efficacy of policy options will be gathered from literature review and from its observed impacts in Singapore. Cost data will be gathered from healthcare institutions, Ministry of Health and published data. Sensitivity analysis such as threshold analysis and scenario analysis will be conducted.

Ethics And Dissemination: Ethics approval was not required for this study. The study findings will be disseminated through peer-reviewed journals.

Citing Articles

A systematic literature review on public health and healthcare resources for pandemic preparedness planning.

Beishuizen B, Stein M, Buis J, Tostmann A, Green C, Duggan J BMC Public Health. 2024; 24(1):3114.

PMID: 39529010 PMC: 11552315. DOI: 10.1186/s12889-024-20629-z.

Investigation on the possibility of dynamic COVID-Zero strategy in China: a population-based transmission model analysis and economic evaluation.

Wang X, Pei S, Wang L, La B, Zhao M, Zhang X BMJ Open. 2023; 13(8):e067294.

PMID: 37536961 PMC: 10401205. DOI: 10.1136/bmjopen-2022-067294.

Understanding the impact of lockdowns on short-term excess mortality in Australia.

Clarke P, Leigh A BMJ Glob Health. 2022; 7(11).

PMID: 36368766 PMC: 9659711. DOI: 10.1136/bmjgh-2022-009032.

References

Appleby J . Will covid-19 vaccines be cost effective-and does it matter?. BMJ. 2020; 371:m4491. DOI: 10.1136/bmj.m4491. View

Menzies N, Soeteman D, Pandya A, Kim J . Bayesian Methods for Calibrating Health Policy Models: A Tutorial. Pharmacoeconomics. 2017; 35(6):613-624. PMC: 5448142. DOI: 10.1007/s40273-017-0494-4. View

Sanders G, Neumann P, Basu A, Brock D, Feeny D, Krahn M . Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA. 2016; 316(10):1093-103. DOI: 10.1001/jama.2016.12195. View

Pitman R, Fisman D, Zaric G, Postma M, Kretzschmar M, Edmunds J . Dynamic transmission modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--5. Value Health. 2012; 15(6):828-34. PMC: 7110742. DOI: 10.1016/j.jval.2012.06.011. View

Baden L, El Sahly H, Essink B, Kotloff K, Frey S, Novak R . Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020; 384(5):403-416. PMC: 7787219. DOI: 10.1056/NEJMoa2035389. View

Garrigues E, Janvier P, Kherabi Y, Le Bot A, Hamon A, Gouze H . Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect. 2020; 81(6):e4-e6. PMC: 7445491. DOI: 10.1016/j.jinf.2020.08.029. View

Vanni T, Karnon J, Madan J, White R, Edmunds W, Foss A . Calibrating models in economic evaluation: a seven-step approach. Pharmacoeconomics. 2010; 29(1):35-49. DOI: 10.2165/11584600-000000000-00000. View

Prosser L, Bridges C, Uyeki T, Hinrichsen V, Meltzer M, Molinari N . Health benefits, risks, and cost-effectiveness of influenza vaccination of children. Emerg Infect Dis. 2006; 12(10):1548-58. PMC: 3290928. DOI: 10.3201/eid1210.051015. View

Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D . Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Int J Technol Assess Health Care. 2013; 29(2):117-22. DOI: 10.1017/S0266462313000160. View

10.

. Meeting the challenge of long COVID. Nat Med. 2020; 26(12):1803. DOI: 10.1038/s41591-020-01177-6. View

11.

Narayan P, Phan D, Liu G . COVID-19 lockdowns, stimulus packages, travel bans, and stock returns. Financ Res Lett. 2020; 38:101732. PMC: 7440077. DOI: 10.1016/j.frl.2020.101732. View

12.

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

13.

Ping W, Zheng J, Niu X, Guo C, Zhang J, Yang H . Evaluation of health-related quality of life using EQ-5D in China during the COVID-19 pandemic. PLoS One. 2020; 15(6):e0234850. PMC: 7302485. DOI: 10.1371/journal.pone.0234850. View

14.

Neumann P, Cohen J, Kim D, Ollendorf D . Consideration Of Value-Based Pricing For Treatments And Vaccines Is Important, Even In The COVID-19 Pandemic. Health Aff (Millwood). 2020; 40(1):53-61. DOI: 10.1377/hlthaff.2020.01548. View

15.

Ashraf B . Economic impact of government interventions during the COVID-19 pandemic: International evidence from financial markets. J Behav Exp Finance. 2020; 27:100371. PMC: 7323651. DOI: 10.1016/j.jbef.2020.100371. View

16.

Arab-Zozani M, Hashemi F, Safari H, Yousefi M, Ameri H . Health-Related Quality of Life and its Associated Factors in COVID-19 Patients. Osong Public Health Res Perspect. 2020; 11(5):296-302. PMC: 7577388. DOI: 10.24171/j.phrp.2020.11.5.05. View

17.

Kim D, Neumann P . Analyzing the Cost Effectiveness of Policy Responses for COVID-19: The Importance of Capturing Social Consequences. Med Decis Making. 2020; 40(3):251-253. DOI: 10.1177/0272989X20922987. View

18.

Sharma A, Pillai D, Lu M, Doolan C, Leal J, Kim J . Impact of isolation precautions on quality of life: a meta-analysis. J Hosp Infect. 2020; 105(1):35-42. DOI: 10.1016/j.jhin.2020.02.004. View

19.

Polack F, Thomas S, Kitchin N, Absalon J, Gurtman A, Lockhart S . Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27):2603-2615. PMC: 7745181. DOI: 10.1056/NEJMoa2034577. View

20.

Eddy D, Hollingworth W, Caro J, Tsevat J, McDonald K, Wong J . Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. Med Decis Making. 2012; 32(5):733-43. DOI: 10.1177/0272989X12454579. View